Legal & General Group PLC Kezar Life Sciences, Inc. Transaction History

Legal & General Group PLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.31 - $3.06 $71 - $94	-31 Reduced 0.45%	6,814 $16,000
Q1 2023 May 15, 2023	SELL	$3.13 - $7.31 $34,389 - $80,314	-10,987 Reduced 61.61%	6,845 $21,000
Q4 2022 Feb 14, 2023	BUY	$6.39 - $8.8 $6,396 - $8,808	1,001 Added 5.95%	17,832 $125,000
Q3 2022 Nov 14, 2022	BUY	$7.99 - $10.75 $15,228 - $20,489	1,906 Added 12.77%	16,831 $145,000
Q2 2022 Aug 22, 2022	BUY	$4.58 - $17.13 $54,286 - $203,041	11,853 Added 385.84%	14,925 $123,000
Q1 2022 May 16, 2022	BUY	$12.3 - $18.33 $3,517 - $5,242	286 Added 10.27%	3,072 $51,000
Q3 2020 Nov 13, 2020	SELL	$4.36 - $5.5 $1,547 - $1,952	-355 Reduced 11.3%	2,786 $13,000
Q2 2020 Aug 14, 2020	SELL	$3.6 - $7.75 $2,253 - $4,851	-626 Reduced 16.62%	3,141 $16,000
Q1 2020 May 14, 2020	BUY	$2.77 - $5.75 $4,520 - $9,384	1,632 Added 76.44%	3,767 $16,000
Q1 2019 May 15, 2019	BUY	$16.83 - $23.75 $22,804 - $32,181	1,355 Added 173.72%	2,135 $38,000
Q3 2018 Nov 20, 2018	BUY	$15.5 - $21.41 $12,090 - $16,699	780 New	780 $17,000

38.4M

13.8K

600

Ticker KZR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,369,504
Market Cap $510M
Description
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical tria...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.